Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...

The latest trading session saw Vertex Pharmaceuticals (VRTX) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of ...

Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) have been assigned a consensus recommendation ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Vertex, Inc. (NASDAQ:VERX – Free Report) by 53.4% ...

This was the stock's fourth consecutive day of gains.

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

Most of the focus in generative AI has been on text-based interfaces used to generate text, images, and more. The next wave appears to be voice, and it’s ...